UK markets closed

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
10.13+0.06 (+0.61%)
At close: 06:11PM BST
Full screen
Previous close10.07
Bid0.00 x 0
Ask0.00 x 0
Day's range9.96 - 10.47
52-week range9.96 - 10.47
Avg. volumeN/A
Market cap9.091M
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Valneva Establishes an At-the-Market (ATM) Program on Nasdaq

    Saint-Herblain (France), August 15, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an At-the-Market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0 million of American Depositar

  • Globe Newswire

    Valneva Reports H1 2022 Results and Provides Corporate Updates

    Excellent progress on late-stage clinical programs Lyme Disease Vaccine Candidate VLA15 Phase 3 study initiated in August 20221Further positive Phase 2 results reported, including first pediatric data2 Single-Shot Chikungunya Vaccine Candidate VLA1553 Initiation of rolling submission for Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) imminentFinal positive pivotal Phase 3 results reported3Final positive lot-to-lot consistency Phase 3 results reported4 Four m

  • Globe Newswire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S. New York & Saint-Herblain (France), August 8, 2022 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate,